This study collects the clinical data of new-onset ocular myasthenia gravis (OMG) patients, assesses outcomes and adverse effects of different treatment options, and evaluate risk factors of conversion to generalized MG(GMG).
Age >18 years and<75 years;
Willingness to sample collection, imaging study and other disease-related examinations and assessments;
The results of pregnancy tests for female subjects with fertility during the screening period should be negative and effective contraception was used by the patient and her spouse during the study period;
Patients with informed consent;
History of chronic degenerative, psychiatric, or neurologic disorder other than MG that can produce weakness or fatigue;
Patients who may have other diseases that may lead to eyelid drooping, peripheral muscle weakness or diplopia;
Age ≤18 years or ≥75 years;
Patients who have been taking glucocorticoids or associated immunosuppressants due to other immune system diseases;
Patients with newly-onset ocular myasthenia gravis
Cohort
Prospective
Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)
DrugTreatment regimens are determined according to the physician's judgment and preferences of the patients.
Conversion rate from ocular to generalized MG at the last follow-up visit.
Ocular MG patients are followed up to determine the ratio of conversion to generalized disease at the end of follow-up. The clinical records will be retrospectively analyzed to search for risk factors of progressing.
Changes in the ratio of patients who achieve the level 2 of MG Status and Treatment Intensity (MGSTI) scale or better.
Ocular MG patients are followed up to determine the ratio of patients that achieve the status of MGSTI 2 or better at each period piont of follow-up. The clinical records will be retrospectively analyzed to search for risk factors prolonged the regimens reduction.
Changes in proportion of patients with treatment-related adverse events.
Treatment-Related Adverse Events (AEs) are evaluated in patients receiving different treatment protocol
Changes in scores of Quantitative Myasthenia Gravis (QMG) scale and of Absolute and Relative Score of MG(ARS-MG) scales from Baseline.
The improvement of clinic status of OMG patients was assessed by investigators according to QMG and ARS-MG score. The QMG is a 13-item scale which measures ocular, bulbar, limb function and respiratory function. The total score ranges from 0 (no myasthenic findings) to 39 (maximal myasthenic deficits) obtained by summing the responses to each individual item.The ARS-MG is a 8-item scale which has a more detailed measure to assess ocular function . The total score ranges from 0 (no myasthenic findings) to 60 (maximal myasthenic deficits) obtained by summing the responses to each individual item.
Changes in titers of MG antibodies.
MG antibodies are detected at enrollment and the titers of antibodies will be monitored annually.
Improvement of repeated frequency electrical stimulation tests (RNS) and single fiber electromyography (SFEMG).
RNS and SFEMG will be monitored on time to assess the clinic status.
Relapse rate during follow-up period.
Ocular MG patients are followed up to determine the relapse rate at the end of follow-up. The clinical records will be retrospectively analyzed to search for risk factors of recurrence.
Click on the lead sponsor to view all of their trials.
